In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.

However, the stock market largely attributes value to a company based on its ability to generate earnings in the future. Based on Lilly’s next twelve months forward P/E ratio, investors are paying ...

Early adopters of weight-loss drugs have tended to be wealthy because ... They’re thinking about inventory management, how to shift the size curve downward.” Before Handler lost 50 pounds on Zepbound, ...

These injectable therapies, which currently include Ozempic, Wegovy, Zepbound, and Mounjaro, were first used to treat diabetes but have since been adopted for weight loss by entertainment and ...

Pharmaceutical giant Eli Lilly (LLY) is putting $4.5 billion toward building a new site to develop and manufacture drugs.

STAT asked 11 experts, including the FDA commissioner, why the world's wealthiest nation is doing so poorly on cardiovascular ...

Metsera said this was consistent with or better than marketed products, which include Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, and other GLP-1/GIP compounds in clinical development. Cumulative ...

INDIANAPOLIS, Oct. 11, 2024 Based on a Nikkei Asia report, pharmaceutical giant, Eli Lilly (LLY, Financial) expects its weight-loss drug Zepbound to get regulatory clearance in Japan by mid-2025.

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...